Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Vaccines01:30

Cancer Vaccines

926
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
926
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Normothermic Machine Perfusion vs. Static Cold Storage for DBD Liver Transplantation in High-MELD Recipients: A Single-Center Retrospective Study.

Journal of hepato-biliary-pancreatic sciences·2026
Same author

Normothermic Regional Perfusion in Controlled Donation After Circulatory Death: Growing Evidence for Liver Transplantation.

Clinical transplantation·2026
Same author

Molecular Determinants of Per- and Polyfluoroalkyl Substances Binding to Estrogen Receptors.

Toxics·2025
Same author

Uncovering the Tumorigenic Blueprint of PFOS and PFOA Through Multi-Organ Transcriptomic Analysis of Biomarkers, Mechanisms, and Therapeutic Targets.

Current issues in molecular biology·2025
Same author

PLAIG: Protein-Ligand Binding Affinity Prediction Using a Novel Interaction-Based Graph Neural Network Framework.

ACS bio & med chem Au·2025
Same author

Impact of Persistent Endocrine-Disrupting Chemicals on Human Nuclear Receptors: Insights from In Silico and Experimental Characterization.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 7, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.5K

AutoEpiCollect 2.0: A Web-Based Machine Learning Tool for Personalized Peptide Cancer Vaccine Design.

Clifford A Kim1, Nina Shelton1, Madhav Samudrala2

  • 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA.

Molecules (Basel, Switzerland)
|December 31, 2025
PubMed
Summary

AutoEpiCollect 2.0 automates tumor-specific variant identification for personalized cancer vaccines. This software accelerates the design of effective cancer vaccines by streamlining genetic analysis and epitope discovery.

Keywords:
RNA sequencingbreast carcinomacervical intraepithelial neoplasmcervical squamous cell carcinomahuman papillomavirusmachine learningpeptide vaccinepersonalized cancer vaccinetriple negative breast cancer

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.5K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K

Area of Science:

  • Genomics and Bioinformatics
  • Immunology and Vaccine Development
  • Oncology

Background:

  • Personalized cancer vaccines train the immune system against tumor antigens.
  • Previous methods for identifying tumor-specific variants were manual and time-consuming.
  • AutoEpiCollect 1.0 accelerated vaccine design but lacked integrated genetic analysis.

Purpose of the Study:

  • To introduce AutoEpiCollect 2.0, an enhanced software with automated genetic analysis for cancer vaccine development.
  • To streamline the identification and prioritization of tumor-specific variants from individual tumor samples.
  • To demonstrate the application of AutoEpiCollect 2.0 in designing personalized peptide vaccines for cervical and breast cancers.

Main Methods:

  • AutoEpiCollect 2.0 integrates RNA sequencing (RNAseq) data for variant determination.
  • The software cross-references RNAseq data to identify cancer-specific and prognostic gene variants.
  • Two case studies were conducted on cervical squamous cell carcinoma and breast carcinoma samples.

Main Results:

  • AutoEpiCollect 2.0 successfully identified high-potential MHC class I and class II epitopes for both cancer types.
  • Key immunogenic epitopes were identified in cervical cancer (HSPG2, MUC5AC) and breast cancer (BRCA2, AHNAK2).
  • The software reduced the time for identifying tumor antigens and streamlined variant analysis.

Conclusions:

  • AutoEpiCollect 2.0 significantly improves the efficiency of personalized cancer vaccine design through automated genomic analysis.
  • The tool enables both patient-specific and population-level vaccine design by analyzing frequent gene variants.
  • AutoEpiCollect 2.0 is available as a free web-based tool for vaccine design.